Product Name:
ErbB4-1
Product Number:
ab-nk235-1
Target Full Name: ErbB4 receptor-tyrosine kinase
Target Alias: HER4; Kinase ErbB4; P180erbB4; P180-erbB4; V-erb-a erythroblastic leukemia viral oncogene 4; MGC138404; CCDS2394.1; ENSG00000178568
Product Type Specific: ErbB4 protein kinase pan-specific antibody
Antibody Code: NK235-1
Antibody Target Type: Pan-specific
Protein UniProt: Q15303
Protein SigNET: ErbB4
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ErbB4 (HER4) sequence peptide Cat. No.: PE-01ATY85
Antibody Immunogen Sequence: LEQQYRALRKYYENC
Antibody Immunogen Description: Corresponds to amino acid residues L42 to C56; in the extracellular domain of the ErbB4 receptor.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human ErbB4 on protein dot blots.
Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Dog | Rat | Mouse.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 150-170 kDa.
Antibody Specificity: Very low
Antibody Cross Reactivity: Medium-weak immunoreactivity on protein dot blots with recombinant human EGFR, and no immunoreactivity with ErbB2.
Related Product 1: ErbB4 (42-56) antibody blocking peptide (Cat. No.: PE-01ATY85)
Related Product 2: ErbB4 expression antibody (Cat. No.: AB-NK235-2)
Related Product 3: ErbB4 expression antibody (Cat. No.: AB-NK235-3)
Related Product 4: ErbB4 Y733 phosphorylation antibody (Cat. No.: AB-PK619)
Related Product 5: ErbB4 Y875 phosphorylation antibody (Cat. No.: AB-PK620)
Related Product 6: ErbB3 expression antibody (Cat. No.: AB-NK231-2)
Related Product 7: ErbB3 expression antibody (Cat. No.: AB-NK231-3)
Related Product 8: ErbB3 expression antibody (Cat. No.: AB-NK231-4)
Related Product 9: ErbB3 Y1289 phosphorylation antibody (Cat. No.: AB-PK616)
Related Product 10: ErbB3 Y1328 phosphorylation antibody (Cat. No.: AB-PK618)
Scientific Background: ErbB4 (HER4) is a protein-tyrosine kinase of the TK group and EGFR family. It is a receptor kinase that upon binding ligands such as neuregulins can drive signalling cascades and many cellular responses to change gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation. Phosphorylation at Y1056 induces interaction with PIK3C2A, and phosphorylation at Y188 induces interaction with Shc1. ErbB4 is a known oncoprotein (OP) and tumour suppressor protein (TSP). Downregulation of ErbB4 has been described in bladder cancer to correlated with oncogensis, but its upregulation is noted in lung cancer. Its mutation pattern in human tumours is very characteristic of a tumour suppressor protein. Mutations in ErbB4 are associated with many types of cancer. Multiple missense mutations in ErbB4 have been found in melanoma patients with increased ErbB4 phosphotransferase activity and transformation ability. Melanoma cells with mutant ErbB4 had reduced cell growth after shRNA knockdown of ErbB4 or treatment with ErbB inhibitor. Mutations in ErbB4 identified in ALS patients showed decreased the auto-phosphorylation of ERBB4 upon neuregulin 1 stimulation in vitro (1). Interestingly, ErbB4 ectodomain fragments were decreased in the CSF from ALS patients, as well as in the plasma of SOD1G93A and TDP-43A315T mice, indicating an involvement of ERBB4 in different ALS subtypes (2). R927Q and R1275W mutations in ErbB4 are associated with amyotrophic lateral sclerosis 19 (ALS19), which is a neurodegenerative disorder affecting upper and lower motor neurons and results in fetal paralysis. This description may include information annotated by UniProt and/or Google AI.